Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entacapone - Novartis/Orion

Drug Profile

Entacapone - Novartis/Orion

Alternative Names: Comtan; Comtess; OR 611

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Bristol-Myers Squibb; Eisai Co Ltd; Novartis; Orion
  • Class Antiparkinsonians; Catechols; Nitriles; Nitrophenols; Small molecules
  • Mechanism of Action Catechol O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Restless legs syndrome

Most Recent Events

  • 31 Dec 2019 Lotus Pharmaceutical acquires marketing and distribution rights for entacapone from Orion Pharma in Hong Kong, Philippines, South Korea and Taiwan
  • 25 Apr 2019 Novartis returns marketing rights in certain European countries for Parkinson's disease to Orion
  • 16 Feb 2017 Eisai acquires marketing rights for entacapone from Orion Pharma in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top